Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round
Summary
Novo Holdings and Jeito Capital co-led the deal, supported by Asabys Partners and existing investors Proceeds to support the clinical development of lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease, with Phase I trials starting imminently Pipeline of next-generation HDAC6 inhibitors (HDAC6i) also to be advanced in significant cardio-metabolic and neurodegenerative diseasesLEUVEN, Belgium 24 March 2025 Augustine Therapeutics NV (Augustine or the Company), a biotechnology company focused on developing new therapies for neuromuscular, neurodegenerative and cardio-metabolic diseases through the inhibition of the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, today announced it has successfully completed its Series A financing round raising a total of EUR 77.7 million (USD 84.8 million). I would like to thank our new and existing investors for their unwavering support as we continue to advance into clinical development.Emmanuelle Coutanceau, PhD, Partner, Seed Investments, Novo Holdings, commented: Our mapping of the HDAC6i landscape has made us confident that Augustines innovative and rigorous approach to medicinal chemistry has yielded molecules with potential to be best-in-class. We look forward to our future collaboration, which shares a common ambition: to accelerate clinical development in order to bring these innovations to patients.Emmanuelle Coutanceau, PhD, Partner at Seed Investments, Novo Holdings, and Mehdi Ainouche, PharmD, Senior Principal at Jeito Capital have joined Augustine Therapeutics Board of Directors. Annette Clancy, Operational Investor at Jeito Capital, and Marie Schroeder, PhD, Vice President at Seed Investments, Novo Holdings will join as Board Observers.Augustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, neurodegenerative and cardio-metabolic diseases through its next-generation approach to selectively inhibit HDAC6. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients access globally, especially in Europe and the United States.